It has been about a month since the last earnings report for Nektar Therapeutics (NKTR). Shares have lost about 38.8% in that time frame, underperforming the S&P 500. Will the recent negative ...

Just days after revealing that it was in discussions with Nektar Therapeutics over a possible merger, PureTech Health has said the negotiations have been terminated by mutual agreement. In a ...

Lilly partnered with Nektar on the drug in 2017, paying $150 million upfront with another $250 million at the back end in development and regulatory milestones. It has agreed to fund 75% of the ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Nektar Therapeutics before investing. In this article, we go over a few key ...

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 8.5% of Aldeyra Therapeutics ...

In the preceding three months, 5 analysts have released ratings for Nektar Therapeutics NKTR, presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

Nektar's market capitalization is currently around $93 million. The firm also pointed to Nektar's cash position of $269.1 million at the end of 2024, which is expected to fund operations through ...